No Data
No Data
Immunic Presses Ahead With MS Drug Despite Phase II Endpoint Miss
William Blair Maintains Immunic(IMUX.US) With Buy Rating
Immunic Price Target Raised to $22 From $19 at Brookline
Immunic's Vidofludimus Calcium Shows Promise in Treating Progressive MS: Analyst Upgrades to Buy
Express News | D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target
Express News | Immunic Shares Are Trading Lower. The Company Reported Phase 2 Data From Its CALLIPER Trial
Rockhoundj : nice and steady
will be best